DEFINITY® News and Updates

Read More


Implementing the American Society of Echocardiography Ultrasound Enhancing Agent Guidelines Into Your Facility's Policy Helps to Ensure the Appropriate Use of DEFINITY® for Improved Patient Care1

Contrast Echo: See the Difference, Experience the Impact

Jonathan R. Lindner, MD, FACC, FASE, Lissa Sugeng, MD, MPH, FACC, FASE, Rajesh Janardhanan, MD, MCRP, FACC, FASE present the Lantheus 2015 ASE Science & Technology Theater Program.

DEFINITY® Delivers Clinical and Economic Value by Improving Diagnostic Accuracy, Lab Efficiency, and Workflow2-4

Reduced resource utilization and per-patient expenses2,3

DEFINITY® helped 33% of patients avoid additional diagnostic procedures.

Eliminated the need for redundant tests by 33%2

Associated with changes in use of vasoactive medications3

Reduced struggle time and may limit sonographer injury4,5*

*Additional studies may be needed.

procedure time4

May increase 
patient throughput4,5

Peer-to-peer programs

Lantheus offers multiple peer-to-peer programs to increase echo quality, enhance lab efficiency, reduce cost, and improve patient care.

IMPROVE quality program

DEFINITY® is committed to delivering customer value through the IMPROVE quality program.

  • Understand your suboptimal echo rate
  • Demonstrate the impact of DEFINITY® through improved image quality and a reduction in overall costs
Sign up for DEFINITY® updates and announcements
Order DEFINITY® products
Explore the potential of DEFINITY® through our webinars


  1. Porter TR, Mulvagh SL, Abdelmoneim SS, et al. Clinical applications of ultrasonic enhancing agents in echocardiography: 2018 American Society of Echocardiography guidelines update. J Am Soc Echocardiogr. 2018;31(3):241-274.

  2. Kurt M, Shaikh KA, Peterson L, et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. J Am Coll Cardiol. 2009;53(9):802-810.

  3. Main ML, Fu JW, Gundrum J, LaPointe NA, Gillam LD, Mulvagh SL. Impact of contrast echocardiography on outcomes in critically ill patients. Am J Cardiol. 2021;150:117-122.

  4. Lester SJ, Askew JW, Hurst RT, et al. Contrast echocardiography: experience in a clinical echocardiography laboratory. J Am Soc Echocardiogr. 2006;19(7):919-923.

  5. Castello R, Bella JN, Rovner A, Swan J, Smith J, Shaw L. Efficacy and time-efficiency of a “sonographer-driven” contrast echocardiography protocol in a high-volume echocardiography laboratory. Am Heart J. 2003;145(3):535-541.


DEFINITY® is indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.



Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration.

  • Assess all patients for the presence of any condition that precludes DEFINITY® administration [see Contraindications (4)].
  • Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].